首頁 > 市場調查報告書 > 製藥

婦科治療

市場調查報告書

商品編碼

1945795

女性健康市場－全球產業規模、佔有率、趨勢、機會及預測（按藥物、應用、地區和競爭格局分類，2021-2031年）

Women's Health Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Application, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球女性健康市場預計將從 2025 年的 167.6 億美元成長到 2031 年的 254.9 億美元，複合年成長率為 7.24%。

該領域涵蓋一系列針對女性特有疾病的藥品、醫療設備和診斷技術，例如婦科癌症、生殖健康問題和自體免疫疾病。推動該領域成長的主要因素是女性人口老化以及需要持續臨床管理的慢性疾病負擔日益加重。例如，美國癌症協會 (ACS) 估計，到 2024 年，美國將新增 310,720 例浸潤性乳癌病例，這凸顯了對能夠支撐市場穩定的醫療解決方案的迫切且普遍的需求。

市場概覽
預測期	2027-2031
市場規模：2025年	167.6億美元
市場規模：2031年	254.9億美元
複合年成長率：2026-2031年	7.24%
成長最快的細分市場	女性不孕症
最大的市場	北美洲

儘管有這些積極跡象，但由於長期資金短缺和複雜的法規環境，市場仍面臨許多障礙。女性生物學研究的資金籌措通常高於其他治療領域，這成為創新的瓶頸。資源分配不均，加上臨床試驗的高成本，阻礙了新治療方法的商業化。因此，資金和監管方面的挑戰有可能延緩重要醫療解決方案的推出，並限制市場充分滿足全球患者群體多樣化需求的能力。

市場促進因素

女性健康科技和數位健康領域的創新蓬勃發展，正成為市場成長的重要催化劑，並正在改變生殖健康和一般醫療保健的提供方式。透過整合人工智慧和行動連線，該領域正在提供個人化的生育管理、月經週期追蹤和更年期支援解決方案，以彌合醫療服務獲取方面的差距，並減少對傳統醫療機構的依賴。 2024年7月，Flo Health獲得由General Atlantic主導的2億美元C輪融資，用於提升其預測能力。此舉證實了消費者工具的商業性可行性，並凸顯了該技術作為醫療保健基礎設施核心要素的擴充性。

政府政策和增加對女性健康研究的投入，正有助於進一步穩定和加速該產業的發展。國家主導正積極應對長期存在的資金短缺問題，降低早期研究在孕產婦健康和子宮內膜異位症等被忽視領域的風險。例如，2024年2月，美國國防高級研究計畫局（ARPA-H）承諾投入1億美元用於突破性的女性健康研究，從而支持高風險、高回報的計劃。 2024年，世界經濟論壇指出，到2040年，消除性別健康差距每年可為全球經濟貢獻1兆美元，這將為系統性投資提供強大的經濟動力。

市場挑戰

長期存在的資金分配不均嚴重限制了女性健康市場的發展，限制了可用於研發的資金。這種資金分配不均造成了創新瓶頸，使製藥和醫療設備公司難以透過昂貴的臨床試驗推出新型治療方法。因此，針對女性生理特徵的治療方法研發面臨重大延誤，限制了慢性病有效管理策略的普及。

投資不足的後果體現在全球研究經費中分配給該領域的比例極低。世界經濟論壇預測，到2024年，除癌症以外的女性疾病的醫療保健研發投資僅佔醫療保健研發總投資的1%。如此微薄的資金限制了市場多元化發展和滿足未被滿足的需求的能力。因此，該領域未能充分發揮其商業性潛力，導致全球很大一部分患者無法獲得足夠的治療選擇。

市場趨勢

生殖和荷爾蒙健康家庭診斷檢測的普及正在改變市場格局，它分散了醫療服務，並克服了臨床就診障礙。在對隱私和便利性的需求驅動下，這一趨勢使患者能夠在家中進行重要的篩檢，例如子宮頸癌和性行為感染感染的篩檢。對於那些往往避免接受傳統骨盆檢查的低頻檢測族群而言，自取樣檢測顯著提高了他們的依從性。 2025年4月，Labcorp推出了一項獲得FDA核准的全國性解決方案，用於為未接受常規HPV檢測的人群提供陰道內自取樣HPV檢測。

同時，非荷爾蒙避孕技術的研發和商業化正成為一股重要趨勢，滿足了那些希望在不承受荷爾蒙副作用的情況下進行計劃生育的患者的需求。這一趨勢的重點是長效可逆避孕方法（LARCs），這些方法利用先進材料確保在無需全身激素干預的情況下也能有效避孕。這些創新為那些不適合或無法接受荷爾蒙避孕的女性提供了必要的替代方案。 2025年1月，Sebela Pharmaceuticals宣布，其無激素銅子宮內避孕器Copper 175mm²在3期臨床試驗中達到了0.94的珍珠指數，證明了這些新型解決方案的有效性。

The Global Women's Health Market is projected to expand from USD 16.76 Billion in 2025 to USD 25.49 Billion by 2031, registering a CAGR of 7.24%. This sector comprises a wide array of pharmaceuticals, medical devices, and diagnostics designed for conditions specifically affecting women, including gynecological cancers, reproductive health issues, and autoimmune diseases. Growth is primarily driven by an aging female demographic and the rising burden of chronic pathologies, which require ongoing clinical management. For instance, the American Cancer Society estimated 310,720 new invasive breast cancer cases in the U.S. in 2024, highlighting the essential, non-discretionary demand for medical solutions that underpins market stability.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 16.76 Billion
Market Size 2031	USD 25.49 Billion
CAGR 2026-2031	7.24%
Fastest Growing Segment	Female Infertility
Largest Market	North America

Despite these positive indicators, the market faces significant hurdles due to historical funding gaps and complex regulatory environments. Research into female-specific biology has often received less capital than other therapeutic areas, creating an innovation bottleneck. This inequitable resource allocation, compounded by high clinical trial costs, hinders the commercialization of new treatments. Consequently, financial and regulatory challenges threaten to slow the rollout of essential healthcare solutions, thereby limiting the market's ability to fully address the diverse needs of the global patient population.

Market Driver

The surge in FemTech and digital health innovations acts as a major catalyst for market growth, transforming the delivery of reproductive and general care. By integrating artificial intelligence and mobile connectivity, this sector offers personalized solutions for fertility management, menstruation tracking, and menopause support, bridging access gaps and reducing dependence on traditional clinics. In July 2024, Flo Health secured a $200 million Series C investment led by General Atlantic to boost its predictive capabilities, a move that validates the commercial viability of direct-to-consumer tools and highlights technological scalability as a core element of the healthcare infrastructure.

Government policies and increased funding for women's healthcare research further stabilize and accelerate the industry. State-sponsored initiatives are actively addressing historic underfunding by de-risking early-stage research in neglected areas such as maternal health and endometriosis. For example, the Advanced Research Projects Agency for Health (ARPA-H) committed $100 million in February 2024 to fund novel female health research, enabling high-risk, high-reward projects. The World Economic Forum noted in 2024 that closing the gender health gap could add $1 trillion annually to the global economy by 2040, providing strong economic motivation for systemic investment.

Market Challenge

Historical funding disparities severely restrict the women's health market by limiting the capital available for research and development. This lack of equitable financial allocation creates an innovation bottleneck, complicating the efforts of pharmaceutical and medical device companies to push novel treatments through expensive clinical trials. As a result, the development of therapies tailored to female biology encounters significant delays, which restricts the availability of effective management strategies for chronic pathologies.

The consequences of this underinvestment are highlighted by the disproportionately small share of global research funding assigned to this sector. According to the World Economic Forum in 2024, only 1 percent of total healthcare R&D investment was allocated to female-specific conditions outside of oncology. This minimal financial commitment hampers the market's ability to diversify its portfolio and address unmet medical needs. Consequently, the sector struggles to reach its full commercial potential, leaving a large portion of the global patient population without adequate therapeutic options.

Market Trends

The proliferation of at-home diagnostic testing for reproductive and hormonal health is reshaping the landscape by decentralizing care and overcoming barriers to clinical access. Driven by a demand for privacy and convenience, this trend allows patients to conduct critical screenings for conditions like cervical cancer and sexually transmitted infections at home. Self-collection methods notably improve compliance among under-screened groups who may avoid traditional pelvic exams. In April 2025, Labcorp introduced a nationwide FDA-approved solution for self-collected vaginal HPV testing, targeting populations not up to date with recommended screenings.

Simultaneously, the development and commercialization of non-hormonal contraceptive innovations are becoming a critical force, addressing patient preferences for family planning without hormonal side effects. This trend focuses on long-acting reversible contraceptives (LARCs) that use advanced materials to ensure efficacy without systemic hormonal intervention. These innovations provide necessary alternatives for women contraindicated for or dissatisfied with hormonal options. In January 2025, Sebela Pharmaceuticals announced that their hormone-free Copper 175mm2 IUD achieved a Pearl Index of 0.94 in a Phase 3 study, validating the effectiveness of these novel solutions.

Key Market Players

AbbVie, Inc
Bayer AG
Merck & Co., Inc
Pfizer, Inc
Teva Pharmaceutical Industries Ltd
Amgen, Inc
Apothecus Pharmaceutical Corp
Blairex Laboratories, Inc
Ferring B.V.
Agile Therapeutics

Report Scope

In this report, the Global Women's Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Women's Health Market, By Drugs

Prolia
Xgeva
Evista
Mirena
Zometa
Others

Women's Health Market, By Application

Female Infertility
Post enopausal Osteoporosis
Endometriosis
Contraception
Others

Women's Health Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Women's Health Market.

Available Customizations:

Global Women's Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Women's Health Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Others)
- 5.2.2. By Application (Female Infertility, Post enopausal Osteoporosis, Endometriosis, Contraception, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Women's Health Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drugs
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Women's Health Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drugs
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Women's Health Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drugs
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Women's Health Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drugs
    - 6.3.3.2.2. By Application

7. Europe Women's Health Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drugs
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Women's Health Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drugs
    - 7.3.1.2.2. By Application
- 7.3.2. France Women's Health Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drugs
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Women's Health Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drugs
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Women's Health Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drugs
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Women's Health Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drugs
    - 7.3.5.2.2. By Application

8. Asia Pacific Women's Health Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drugs
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Women's Health Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drugs
    - 8.3.1.2.2. By Application
- 8.3.2. India Women's Health Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drugs
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Women's Health Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drugs
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Women's Health Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drugs
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Women's Health Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drugs
    - 8.3.5.2.2. By Application

9. Middle East & Africa Women's Health Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drugs
- 9.2.2. By Application
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Women's Health Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drugs
    - 9.3.1.2.2. By Application
- 9.3.2. UAE Women's Health Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drugs
    - 9.3.2.2.2. By Application
- 9.3.3. South Africa Women's Health Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drugs
    - 9.3.3.2.2. By Application

10. South America Women's Health Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drugs
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Women's Health Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drugs
    - 10.3.1.2.2. By Application
- 10.3.2. Colombia Women's Health Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drugs
    - 10.3.2.2.2. By Application
- 10.3.3. Argentina Women's Health Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drugs
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Women's Health Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. AbbVie, Inc
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Bayer AG
15.3. Merck & Co., Inc
15.4. Pfizer, Inc
15.5. Teva Pharmaceutical Industries Ltd
15.6. Amgen, Inc
15.7. Apothecus Pharmaceutical Corp
15.8. Blairex Laboratories, Inc
15.9. Ferring B.V.
15.10. Agile Therapeutics